Hemostemix Inc. (CVE:HEM – Get Free Report) shares rose 18.8% during mid-day trading on Tuesday . The stock traded as high as C$0.20 and last traded at C$0.19. Approximately 298,425 shares changed hands during mid-day trading, a decline of 40% from the average daily volume of 497,673 shares. The stock had previously closed at C$0.16.
Hemostemix Price Performance
The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The stock has a market cap of C$28.42 million, a PE ratio of -5.69 and a beta of 0.20. The business has a 50-day moving average price of C$0.20 and a 200 day moving average price of C$0.12.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What Are Dividend Champions? How to Invest in the Champions
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- How to Invest in Insurance Companies: A Guide
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
